Interview: Bart Roep – Director, Diabetes Expert Center, Leiden…
Winner of the Dutch Prix Corona Gallina in 2011, Prof. Dr. Bart Roep discusses his groundbreaking research into type 1 diabetes; his wishes to deal with the cause rather than…
Address: Albinusdreef 2, 2333 ZA Leiden, the Netherlands
,Netherlands
Tel: +31 71 5269111
Web: https://www.lumc.nl/home/
One of the eight medical centres in the Netherlands, the Leiden University Medical Center (LUMC) has five core tasks:
patient care
scientific research
education
study programmes
continuing education.
The LUMC employs 7000 people.
Patient care is largely focused on highly specialised care, the sort of care that cannot be provided anywhere else. The LUMC also offers a broad package of top-level clinical care, including organ transplants, cardiovascular interventions and all types of bone marrow transplants.
The research conducted in the LUMC is both fundamental and patient- and care-oriented. A considerable portion of the research centres on the translation from fundamental research to its use in patient care (from bench to bedside and vice versa). A good example is the recently opened C.J. Gorter Center, one of the world’s prominent centres in the area of MRI research.
The C.J. Gorter Center has installed the first 7Tesla MRI scanner in the Netherlands for use with humans. The research in the LUMC will be aimed at early diagnosis of Alzheimer’s, a better understanding of migraine, the energy economy in healthy people and patients with diabetes, and the process of ageing. Important research themes in the LUMC are: ageing, neurosciences, vascular medicine, infectious diseases and immunology, cancer immunotherapy, regenerative medicine, oncogenetics, genetic epidemiology and bio-informatics.
The LUMC offers degree courses in Medicine and Biomedical Sciences. The training of medical specialists is also a core task of the LUMC. Medical specialists are trained in 27 specialities in collaborative clusters of general hospitals in the vicinity.
The Boerhaave Committee is another part of the LUMC. Its focus is the provision of high-quality training at post-academic and post-graduate as well post-vocational levels.
patient care
scientific research
education
study programmes
continuing education
Winner of the Dutch Prix Corona Gallina in 2011, Prof. Dr. Bart Roep discusses his groundbreaking research into type 1 diabetes; his wishes to deal with the cause rather than…
Your role as Chair of the Executive Board is a mix between CEO and CMO. On a daily basis, which do you see yourself as more – the Chief Executive…
Speaking to PharmaBoardroom in the context of our upcoming InFocus special report on HIV, Access to Medicine Foundation CEO Jayasree Iyer looks back on pharma’s successes and failures in access…
Marijn Verhoef, Director of Operations and Research at the Access to Medicine Foundation examines the interconnected challenges of drug shortages and antimicrobial resistance. Verhoef urges decisive and urgent action from…
The EMA’s Peter Arlett looks back on two years of the Accelerating Clinical Trials in the European Union (ACT EU) initiative which aims to improve the environment for clinical trials…
New methodology for the 2024 Access to Medicine Index promises a stronger attempt to quantify whether drugs, vaccines, and diagnostics are actually making it all the way to patients in…
Claudia Martínez, generic & biosimilar medicines programme manager at the Access to Medicine Foundation, draws from a recent AMF report to outline what more generics companies can be doing to…
As part of a wide-ranging conversation with PharmaBoardroom published earlier this month, European Medicines Agency (EMA) Executive Director Emer Cooke laid out four of the Agency’s core focus areas for…
In conversation at DIA Europe 2023 in Basel, European Medicines Agency Executive Director Emer Cooke looks back at the lessons EMA has taken from the COVID-19 pandemic response, outlines the…
The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this…
The latest news from the Dutch pharma, biotech and healthcare industries, including the bullish comments of Argenx CEO Tim Van Hauwermeiren following the successful launch of its Vyvgart product; cancer…
The European Medicines Agency (EMA), the EU body responsible for the evaluation of medicinal products for use within the European Union, concluded a vote on Monday evening in Brussels following…
Leo de Haan of Aurobindo discusses how to maintain a profitable business in times of rock-bottom generics prices in the Netherlands, the resulting second pillar of specialty products for the…
Despite lacking a national champion to bolster its innovative eco-system since the 2007 acquisition of Organon by Schering Plough, the Netherlands nevertheless still sits in fourth position on the 2015…
See our Cookie Privacy Policy Here
